Glaucoma Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Prostaglandin Analogs, Beta-blockers, Adrenergic Agonists, Carbonic Anhydrase Inhibitors); By Distribution Channel; By Disease Type; By Region; Segment Forecast, 2022 - 2030

Glaucoma Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Prostaglandin Analogs, Beta-blockers, Adrenergic Agonists, Carbonic Anhydrase Inhibitors); By Distribution Channel; By Disease Type; By Region; Segment Forecast, 2022 - 2030

The global glaucoma market size is expected to reach USD 9.77 billion by 2030, according to a new study by Polaris Market Research. The report “Glaucoma Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Prostaglandin analogs, Beta-blockers, Adrenergic agonists, Carbonic anhydrase inhibitors, and Others); By Distribution Channel; By Disease Type; By Region; Segment Forecast, 2022 – 2030” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The rising prevalence of glaucoma across the globe is the key factor bolstering market growth over the forecast period. Glaucoma is gradually becoming more common among the senior population. The elderly population’s increased use of technology, such as smartphones and laptops, is contributing to the rise in glaucoma cases. As per the International Agency for the Prevention of Blindness, in the entire world, glaucoma is the third most common cause of blindness and the fourth most prevalent cause of visual loss.

According to estimates, at least 3 million people are currently blind, and 4 million have glaucoma-related mild to severe vision problems. At least 50 percent of glaucoma sufferers are not aware of their condition. 90% of glaucoma cases in some developing nations go undiagnosed.

Further, it also estimated that, in 2018, glaucoma affected 1.9% of Americans over 40 age. According to estimates, there will be 112 million cases of glaucoma by 2040, up from 76 million in 2020. Vision impairment has become a prominent public health issue as the world’s population ages.

One billion people worldwide in 2020 have presbyopia or impaired distance vision. This number is projected to rise to 1/8 billion by 2050. In later life (>60 years), common causes of visual impairment, such as cataracts, glaucoma, age-related vision problems, diabetes mellitus, and presbyopia, are increasingly common.

The market for glaucoma is expanding at a remarkable rate, primarily because of the rising elderly population. The risk of glaucoma is most significant in the elderly population, yet it can also afflict people of other ages. People with diabetes and a history of glaucoma in their families are two more high-risk populations. Other market-driving drivers include rising awareness, rising healthcare costs, and screening.

Glaucoma Market Report Highlights

  • The clinics segment is anticipated to grow at a fastest CAGR over the forecast period. The number of glaucoma cases worldwide has increased, which has increased the demand for ophthalmic clinic treatments. The necessity for ophthalmology clinics in the medical sector has increased as a result of an increase in eye illnesses and technological advancements.
  • Beta blockers segment accounted for a significant revenue share in 2021. Due to their relative affordability, beta blockers are the most frequently chosen medication by patients. The market is seeing an increase in demand for beta-blocker eye drops due to rising treatment costs.
  • Asia Pacific is expected to witness fastest growth over the projected period. The market’s demand for glaucoma medications has expanded as a result of rising government financing for the medical sector.
  • The global glaucoma market is highly competitive owing to the existence of large market players with a global presence including Allergan PLC, Bausch & Lomb Incorporated, Cipla Incorporation, Inotek Pharmaceuticals, Merck KGaA, Novartis AG, Pfizer Incorporation, Teva Pharmaceutical Industries Ltd., and Valeant Pharmaceuticals International, Inc.
Polaris Market Research has segmented the glaucoma market report based on drug class, distribution channel, disease type, and region:

Glaucoma, Drug Class Outlook (Revenue – USD Billion, 2018 – 2030)
  • Prostaglandin analogs
  • Beta-blockers
  • Adrenergic agonists
  • Carbonic anhydrase inhibitors
  • Others
Glaucoma, Distribution Channel Outlook (Revenue – USD Billion, 2018 – 2030)
  • Hospital pharmacy
  • Retail pharmacy
  • Online Pharmacy
Glaucoma, Disease Type Outlook (Revenue – USD Billion, 2018 – 2030)
  • Open-angle glaucoma
  • Angle-closure glaucoma
  • Others
Glaucoma, Regional Outlook (Revenue – USD Billion, 2018 – 2030)
  • North America
  • U.S
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa


1. Introduction
1.1. Report Description
1.1.1. Objectives of the Study
1.1.2. Market Scope
1.1.3. Assumptions
1.2. Stakeholders
2. Executive Summary
2.1. Market Highlights
3. Research Methodology
3.1. Overview
3.1.1. Data Mining
3.2. Data Sources
3.2.1. Primary Sources
3.2.2. Secondary Sources
4. Global Glaucoma Market Insights
4.1. Glaucoma – Industry Snapshot
4.2. Glaucoma Market Dynamics
4.2.1. Drivers and Opportunities
4.2.1.1. Rising prevalence Glaucoma to bolster market growth
4.2.1.2. Increasing product under pipeline and recent product launches to accelerate growth
4.2.2. Restraints and Challenges
4.2.2.1. Drug recalls by major players is projected to hinder demand for Glaucoma therapeutics
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers (Moderate)
4.3.2. Threats of New Entrants: (Low)
4.3.3. Bargaining Power of Buyers (Moderate)
4.3.4. Threat of Substitute (Moderate)
4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. Glaucoma Market Industry Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis
5. Global Glaucoma Market, by Drug Class
5.1. Key Findings
5.2. Introduction
5.2.1. Global Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
5.3. Prostaglandin Analogs
5.3.1. Global Glaucoma Market, by Prostaglandin Analogs, by Region, 2018 - 2030 (USD Billion)
5.4. Beta-blockers
5.4.1. Global Glaucoma Market, by Beta-blockers, by Region, 2018 - 2030 (USD Billion)
5.5. Adrenergic Agonists
5.5.1. Global Glaucoma Market, by Adrenergic Agonists, by Region, 2018 - 2030 (USD Billion)
5.6. Carbonic Anhydrase Inhibitors
5.6.1. Global Glaucoma Market, by Carbonic Anhydrase Inhibitors, by Region, 2018 - 2030 (USD Billion)
5.7. Others
5.7.1. Global Other Glaucoma Market, by Region, 2018 - 2030 (USD Billion)
6. Global Glaucoma Market, by Distribution Channel
6.1. Key Findings
6.2. Introduction
6.2.1. Global Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
6.3. Hospital pharmacy
6.3.1. Global Glaucoma Market, by Hospital pharmacy, by Region, 2018 - 2030 (USD Billion)
6.4. Retail pharmacy
6.4.1. Global Glaucoma Market, by Retail pharmacy, by Region, 2018 - 2030 (USD Billion)
6.5. Online Pharmacy
6.5.1. Global Glaucoma Market, by Online Pharmacy, by Region, 2018 - 2030 (USD Billion)
7. Global Glaucoma Market, by Disease Type
7.1. Key Findings
7.2. Introduction
7.2.1. Global Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
7.3. Open-angle
7.3.1. Global Glaucoma Market, by Open-angle, by Region, 2018 - 2030 (USD Billion)
7.4. Angle-closure
7.4.1. Global Glaucoma Market, by Angle-closure, by Region, 2018 - 2030 (USD Billion)
7.5. Others
7.5.1. Global Other Glaucoma Market, by Region, 2018 - 2030 (USD Billion)
8. Global Glaucoma Market, by Geography
8.1. Key findings
8.2. Introduction
8.2.1. Glaucoma Market Assessment, By Geography, 2018 - 2030 (USD Billion)
8.3. Glaucoma Market – North America
8.3.1. North America: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
8.3.2. North America: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
8.3.3. North America: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
8.3.4. Glaucoma Market – U.S.
8.3.4.1. U.S.: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
8.3.4.2. U.S.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
8.3.4.3. U.S.: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
8.3.5. Glaucoma Market – Canada
8.3.5.1. Canada: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
8.3.5.2. Canada.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
8.3.5.3. Canada: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
8.4. Glaucoma Market – Europe
8.4.1. Europe: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
8.4.2. Europe.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
8.4.3. Europe: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
8.4.4. Glaucoma Market – UK
8.4.4.1. UK: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
8.4.4.2. UK.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
8.4.4.3. UK: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
8.4.5. Glaucoma Market – France
8.4.5.1. France: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
8.4.5.2. France.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
8.4.5.3. France: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
8.4.6. Glaucoma Market – Germany
8.4.6.1. Germany: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
8.4.6.2. Germany.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
8.4.6.3. Germany: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
8.4.7. Glaucoma Market – Italy
8.4.7.1. Italy: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
8.4.7.2. Italy.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
8.4.7.3. Italy: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
8.4.8. Glaucoma Market – Spain
8.4.8.1. Spain: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
8.4.8.2. Spain.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
8.4.8.3. Spain: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
8.4.9. Glaucoma Market – Netherlands
8.4.9.1. Netherlands: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
8.4.9.2. Netherlands.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
8.4.9.3. Netherlands: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
8.4.10. Glaucoma Market – Russia
8.4.10.1. Russia: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
8.4.10.2. Russia.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
8.4.10.3. Russia: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
8.5. Glaucoma Market – Asia Pacific
8.5.1. Asia Pacific: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
8.5.2. Asia Pacific.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
8.5.3. Asia Pacific: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
8.5.4. Glaucoma Market – China
8.5.4.1. China: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
8.5.4.2. China.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
8.5.4.3. China: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
8.5.5. Glaucoma Market – India
8.5.5.1. India: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
8.5.5.2. India.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
8.5.5.3. India: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
8.5.6. Glaucoma Market – Malaysia
8.5.6.1. Malaysia: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
8.5.6.2. Malaysia.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
8.5.6.3. Malaysia: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
8.5.7. Glaucoma Market – Japan
8.5.7.1. Japan: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
8.5.7.2. Japan.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
8.5.7.3. Japan: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
8.5.8. Glaucoma Market – Indonesia
8.5.8.1. Indonesia: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
8.5.8.2. Indonesia.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
8.5.8.3. Indonesia: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
8.5.9. Glaucoma Market – South Korea
8.5.9.1. South Korea: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
8.5.9.2. South Korea.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
8.5.9.3. South Korea: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
8.6. Glaucoma Market – Middle East & Africa
8.6.1. Middle East & Africa: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
8.6.2. Middle East & Africa.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
8.6.3. Middle East & Africa: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
8.6.4. Glaucoma Market – Saudi Arabia
8.6.4.1. Saudi Arabia: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
8.6.4.2. Saudi Arabia.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
8.6.4.3. Saudi Arabia: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
8.6.5. Glaucoma Market – UAE
8.6.5.1. UAE: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
8.6.5.2. UAE.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
8.6.5.3. UAE: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
8.6.6. Glaucoma Market – Israel
8.6.6.1. Israel: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
8.6.6.2. Israel.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
8.6.6.3. Israel: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
8.6.7. Glaucoma Market – South Africa
8.6.7.1. South Africa: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
8.6.7.2. South Africa.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
8.6.7.3. South Africa: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
8.7. Glaucoma Market – Latin America
8.7.1. Latin America: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
8.7.2. Latin America.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
8.7.3. Latin America: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
8.7.4. Glaucoma Market – Mexico
8.7.4.1. Mexico: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
8.7.4.2. Mexico.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
8.7.4.3. Mexico: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
8.7.5. Glaucoma Market – Brazil
8.7.5.1. Brazil: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
8.7.5.2. Brazil.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
8.7.5.3. Brazil: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
8.7.6. Glaucoma Market – Argentina
8.7.6.1. Argentina: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
8.7.6.2. Argentina.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
8.7.6.3. Argentina: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
9. Competitive Landscape
9.1. Expansion and Acquisition Analysis
9.1.1. Expansion
9.1.2. Acquisitions
9.2. Partnerships/Collaborations/Agreements/Exhibitions
10. Company Profiles
10.1. Allergan PLC
10.1.1. Company Overview
10.1.2. Financial Performance
10.1.3. Product Benchmarking
10.1.4. Recent Development
10.2. Aristo Pharmaceuticals Pvt. Ltd
10.2.1. Company Overview
10.2.2. Financial Performance
10.2.3. Product Benchmarking
10.2.4. Recent Development
10.3. Aerie Pharmaceuticals Company
10.3.1. Company Overview
10.3.2. Financial Performance
10.3.3. Product Benchmarking
10.3.4. Recent Development
10.4. Akorn operating company LLC
10.4.1. Company Overview
10.4.2. Financial Performance
10.4.3. Product Benchmarking
10.4.4. Recent Development
10.5. Bausch & Lomb Incorporated
10.5.1. Company Overview
10.5.2. Financial Performance
10.5.3. Product Benchmarking
10.5.4. Recent Development
10.6. Cipla Incorporation
10.6.1. Company Overview
10.6.2. Financial Performance
10.6.3. Product Benchmarking
10.6.4. Recent Development
10.7. Fera Pharmaceuticals, LLC
10.7.1. Company Overview
10.7.2. Financial Performance
10.7.3. Product Benchmarking
10.7.4. Recent Development
10.8. Inotek Pharmaceuticals
10.8.1. Company Overview
10.8.2. Financial Performance
10.8.3. Product Benchmarking
10.8.4. Recent Development
10.9. Merck KGaA
10.9.1. Company Overview
10.9.2. Financial Performance
10.9.3. Product Benchmarking
10.9.4. Recent Development
10.10. Novartis AG
10.10.1. Company Overview
10.10.2. Financial Performance
10.10.3. Product Benchmarking
10.10.4. Recent Development
10.11. Pfizer Incorporation
10.11.1. Company Overview
10.11.2. Financial Performance
10.11.3. Product Benchmarking
10.11.4. Recent Development
10.12. Santen Pharmaceutical Co., Ltd
10.12.1. Company Overview
10.12.2. Financial Performance
10.12.3. Product Benchmarking
10.12.4. Recent Development
10.13. Teva Pharmaceutical Industries Ltd
10.13.1. Company Overview
10.13.2. Financial Performance
10.13.3. Product Benchmarking
10.13.4. Recent Development
10.14. Valeant Pharmaceuticals International, Inc.
10.14.1. Company Overview
10.14.2. Financial Performance
10.14.3. Product Benchmarking
10.14.4. Recent Development

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings